



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/005,842	12/07/2001	Jian Ni	1488.131000A	4105
28730	7590	04/12/2005	EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			KAUFMAN, CLAIRE M	
		ART UNIT	PAPER NUMBER	
		1646		

DATE MAILED: 04/12/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/005,842	NI ET AL.	
	Examiner Claire M. Kaufman	Art Unit 1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 24 January 2005.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 35-72,75,83,92,99-133,152-178 and 180-203 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) 35-72,75,83,92,127-133,160-178 and 180-203 is/are allowed.
- 6) Claim(s) 99-126 and 152-159 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date: _____. |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>11/08/04</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

Response to Arguments

The rejections of the previous Office action are withdrawn in view of the amendment to the claims. Two new rejections appear below.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 152-159 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated polypeptide consisting of an amino acid sequence at least 90% identical to amino acids 1 to 133 of SEQ ID NO:2, wherein said polypeptide inhibits apoptosis or for an isolated soluble polypeptide comprising an amino acid sequence at least 90% identical to amino acids 1 to 133 of SEQ ID NO:2, does not reasonably provide enablement for a non-soluble polypeptide comprising an amino acid sequence at least 90% identical to amino acids 1 to 133 of SEQ ID NO:2. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Because the claimed polypeptide must inhibit apoptosis and because the full-length protein of SEQ ID NO:2 is a transmembrane receptor protein that induces apoptosis upon binding of its ligand, in order for the polypeptide to inhibit apoptosis, it must be soluble or have no intracellular signaling region so it binds the ligand before the ligand can activate the transmembrane receptor protein. There is no guidance or example in the specification of how to make a polypeptide comprising a sequence 90% identical to amino acids 1-133 of SEQ ID NO:2, *i.e.*, the extracellular domain (ECD), which inhibits apoptosis unless it is a soluble polypeptide. The specification in Example 6 (p. 53) shows a DR5 ECD-Fc fusion that is soluble and blocks TRAIL-induced apoptosis. The prior art does not provide guidance or examples of modified ECDs of death domain receptors which are capable of inhibiting apoptosis, though there are

examples of soluble ECDs of the receptors as well as membrane bound death domain receptors lacking their intracellular signaling domain(s) which can inhibit apoptosis. It would require undue experimentation to use the invention commensurate in scope with the claims.

Claims 99-126 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Elements required for practicing a claimed invention must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. When biological material is required to practice an invention, and if it is not so obtainable or available, the enablement requirements of 35 USC §112, first paragraph, may be satisfied by a deposit of the material. See 37 CFR 1.802.

The specification does not provide a repeatable method for obtaining the cDNA clone in ATCC Deposit No. 97920 and it does not appear to be a readily available material. Even though the cDNA clone was deposited as ATCC Deposit No. 97920 on March 7, 1997 (e.g., p. 7, beginning line 20) the full requirements for deposit have not been met so as to satisfy the requirements of 35 USC §112, first paragraph.

If a deposit is made under the terms of the Budapest Treaty, then an affidavit or declaration by Applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating that the deposit has been made under the terms of the Budapest Treaty and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent, would satisfy the deposit requirements. See 37 CFR 1.808.

If a deposit is not made under the terms of the Budapest Treaty, then an affidavit or Declaration by Applicants or someone associated with the patent owner who is in a position to make such assurances, or a statement by an attorney of record over his or her signature, stating

Art Unit: 1646

that the deposit has been made at an acceptable depository and that the following criteria have been met:

- (a) during the pendency of the application, access to the deposit will be afforded to one determined by the Commissioner to be entitled thereto;
- (b) all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent;
- (c) the deposit will be maintained for a term of at least thirty (30) years and at least five (5) years after the most recent request for the furnishing of a sample of the deposited material;
- (d) a viability statement in accordance with the provisions of 37 CFR 1.807; and
- (e) the deposit will be replaced should it become necessary due to inviability, contamination or loss of capability to function in the manner described in the specification. In addition the identifying information set forth in 37 CFR 1.809(d) should be added to the specification. See 37 CFR 1.803-1.809 for additional explanation of these requirements.

Prior Art

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. On the IDS file 11/8/04; Applicants cite three US PreGrant Publications of Holtzman (AF2-AH2). These applications disclose Tango 63 and splice variants thereof, which are the same as or share high identity with to SEQ ID NO:2 of the instant application. However, the earliest priority applications of Holtzman to disclose Tango 63 are 09/757,421, filed 1/10/01, and 08/843,652, filed 4/16/97; and, therefore, none of the Holtzman documents are available as prior art.

Conclusion

Claims 35-72, 75, 83, 92, 127-133, 160-178 and 180-203 are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire M. Kaufman, whose telephone number is (571) 272-0873. Dr. Kaufman can generally be reached Monday, Tuesday and Thursday from 8:30AM to 2:30PM.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached at (571) 272-0829.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Art Unit: 1646

Official papers filed by fax should be directed to (571) 273-8300. NOTE: If applicant *does* submit a paper by fax, the original signed copy should be retained by the applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Claire M. Kaufman, Ph.D.


Patent Examiner, Art Unit 1646

April 4, 2005